



Genocea Biosciences Hires Ravi Venkataramani, Ph.D. as Vice President, Business Development

Brings Extensive Deal-Making Experience to Novel Vaccine Company

Cambridge, Mass. – June 20, 2011/Businesswire – Genocea Biosciences, Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced the appointment of Ravi Venkataramani, Ph.D., as Vice President, Business Development. Dr. Venkataramani joins Genocea to focus on business and corporate development.

“We are very pleased to welcome Ravi to Genocea,” said Chip Clark, President and Chief Executive Officer of Genocea. “His extensive deal-making experience will help ensure that Genocea can best capitalize on our unique antigen discovery capabilities and expanding pipeline of novel programs, to support our strategy of developing breakthrough vaccines.”

“Using its unique ability to identify validated T cell antigens rapidly, Genocea is poised to make meaningful contributions to the patients and physicians fighting major infectious diseases,” said Dr. Venkataramani. “I am excited to join Genocea as it transforms into a development stage company through with its lead program, a novel therapeutic vaccine for herpes simplex virus type 2.”

Dr. Venkataramani has more than 10 years experience in corporate strategy, portfolio management and deal making. Most recently, he served as the Director of Business Development at MedImmune. While at MedImmune, he led several key strategic, product and technology deals that in aggregate were worth \$150 million in upfront value plus \$1.5 billion in contingent milestones. In addition, he shared responsibilities for building and managing the respiratory, immunology and autoimmunity drug portfolio of the company. Prior to joining MedImmune, he advised senior management of Fortune-100 clients on all aspects of corporate strategy and execution at Booz, Allen & Hamilton (now Booz & Co). He holds a B.S. from the University of Wisconsin and a Ph.D. in biochemistry and molecular biophysics from the University of Pennsylvania.

About Genocea

Genocea Biosciences is a vaccine discovery and development company targeting major infectious diseases with high unmet medical needs, in which T cell responses help confer protection. The company’s transformational discovery platform mines the natural immune response across diverse human populations in a way that radically reduces the risk, cost and time associated with antigen discovery. Genocea is currently developing vaccines for herpes simplex virus type-2 (therapeutic and prophylactic); *Chlamydia trachomatis*, a sexually transmitted disease agent causing an estimated 90 million cases worldwide; *Streptococcus pneumoniae*, the leading killer of children under the age of 5 worldwide; and *Plasmodium falciparum* (malaria), of which there are more than 100 million cases globally. Visit www.genocea.com for more information.

CONTACT: Chip Clark, President and CEO, Genocea Biosciences +1.617.876.8191